1298 related articles for article (PubMed ID: 19768639)
1. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
2. [Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension].
Kiliçkesmez K; Küçükoğlu MS
Anadolu Kardiyol Derg; 2010 Sep; 10 Suppl 2():16-8. PubMed ID: 20819751
[TBL] [Abstract][Full Text] [Related]
3. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase 5 inhibitors for erectile dysfunction.
Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
[TBL] [Abstract][Full Text] [Related]
5. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
[TBL] [Abstract][Full Text] [Related]
6. Tadalafil for the treatment of pulmonary arterial hypertension.
Rosenzweig EB
Expert Opin Pharmacother; 2010 Jan; 11(1):127-32. PubMed ID: 20001434
[TBL] [Abstract][Full Text] [Related]
7. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
Gresser U; Gleiter CH
Eur J Med Res; 2002 Oct; 7(10):435-46. PubMed ID: 12435622
[TBL] [Abstract][Full Text] [Related]
8. [Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension].
Sakuma M; Shirato K
Nihon Rinsho; 2008 Nov; 66(11):2157-61. PubMed ID: 19051736
[TBL] [Abstract][Full Text] [Related]
9. Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release.
Toque HA; Priviero FB; Teixeira CE; Claudino MA; Baracat JS; Fregonesi A; De Nucci G; Antunes E
Urology; 2009 Jul; 74(1):216-21. PubMed ID: 19371941
[TBL] [Abstract][Full Text] [Related]
10. Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy.
Rondelet B; Kerbaul F; Van Beneden R; Motte S; Fesler P; Hubloue I; Remmelink M; Brimioulle S; Salmon I; Ketelslegers JM; Naeije R
Circulation; 2004 Oct; 110(15):2220-5. PubMed ID: 15466636
[TBL] [Abstract][Full Text] [Related]
11. Sudden sensorineural hearing loss associated with vardenafil.
Snodgrass AJ; Campbell HM; Mace DL; Faria VL; Swanson KM; Holodniy M
Pharmacotherapy; 2010 Jan; 30(1):112. PubMed ID: 20030481
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
[TBL] [Abstract][Full Text] [Related]
13. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue.
Uckert S; Sormes M; Kedia G; Scheller F; Knapp WH; Jonas U; Stief CG
Urology; 2008 Mar; 71(3):526-30. PubMed ID: 18342202
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
Ghofrani HA; Grimminger F
Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S311-4. PubMed ID: 17139594
[TBL] [Abstract][Full Text] [Related]
15. Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors.
Taylor J; Baldo OB; Storey A; Cartledge J; Eardley I
BJU Int; 2009 May; 103(10):1392-5. PubMed ID: 19154494
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
Shapiro S; Traiger G; Hill W; Zhang L; Doran AK
Cardiovasc Ther; 2013 Oct; 31(5):274-9. PubMed ID: 23841794
[TBL] [Abstract][Full Text] [Related]
17. [Phosphodiesterase inhibitors: effectiveness and new applications].
van Driel MF
Ned Tijdschr Geneeskd; 2006 Jul; 150(29):1613-6. PubMed ID: 16901064
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
Vickers MA; Satyanarayana R
Int J Impot Res; 2002 Dec; 14(6):466-71. PubMed ID: 12494279
[TBL] [Abstract][Full Text] [Related]
19. Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case series of 12 patients.
Tay EL; Geok-Mui MK; Poh-Hoon MC; Yip J
Int J Cardiol; 2008 Apr; 125(3):416-7. PubMed ID: 17407795
[No Abstract] [Full Text] [Related]
20. PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.
Rosen RC; McKenna KE
Annu Rev Sex Res; 2002; 13():36-88. PubMed ID: 12836729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
